IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Evidence

Parkinson's disease

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

A 2026 peer-reviewed case report describes one patient treated with low-dose Ibogaine hydrochloride over 80 days using validated Parkinson's instruments.

Confidence: LowSource type: Study
Evidence level
case report watchlist
Sample sizes
One published case report in the current public watchlist.
Design quality
A single case cannot establish efficacy, generalizability, or safety.
Outcomes
Motor symptoms, quality of life, fatigue, mood, sleep, freezing of gait, and adverse events need structured follow-up.
Limitations
One-patient evidence is highly uncertain and vulnerable to placebo, expectation, medication changes, and disease variability.
Safety signals
Age, cardiac status, neurological comorbidity, drug interactions, sleep worsening, and medication changes.
What is not proven
Ibogaine is not proven as a Parkinson's treatment.
Best next source
Journal of Psychedelic Studies 2026 case report via University of Otago.